ESTRO 2024 - Abstract Book

S1458

Clinical - Head & neck

ESTRO 2024

Conclusion:

The UPGRADE-RT trial demonstrates that reduction of the elective radiation dose is safe but did not result in better normalcy of diet scores compared to the control group. However, normalcy of diet scores were excellent in both groups and much higher than anticipated. This is the second randomized controlled trial demonstrating the safety of a reduced elective radiation dose in patients receiving definitive radiotherapy for oropharyngeal-, laryngeal- and hypopharyngeal squamous cell carcinoma and should therefore be considered to become the new standard of care [6].

Keywords: elective neck irradiation, dose de-escalation, pet

References:

[1] van den Bosch S, Vogel WV, Raaijmakers CP, et al. Implications of improved diagnostic imaging of small nodal metastases in head and neck cancer: radiotherapy target volume transformation and dose de-escalation. Radiother Oncol. 2018;128(3): 472-478. [2] Kaanders J, van den Bosch S, Dijkema T, et al. Advances in cancer imaging require renewed radiotherapy dose and target volume concepts. Radiother Oncol. 2020;148:140-142. [3] van den Bosch S, Dijkema T, Kunze-Busch MC, et al. Uniform FDG-PET guided GRAdient dose prEscription to reduce late radiation toxicity (UPGRADE-RT): study protocol for a randomized clinical trial with dose reduction to the elective neck in head and neck squamous cell carcinoma. BMC Cancer. 2017;17(1):208 [4] List MA, Ritter-Sterr C, Lansky SB. A performance status scale for head and neck cancer patients. Cancer. 1990;66:564-9. [5] M. Cox, S. van den Bosch, P. Doornaert, et al. OC-0829 A randomized trial of reduced elective neck dose in head & neck cancer: acute toxicity (NCT02442375). Radiother Oncol. 2023;182(Supp 1): S700-S701.